MedTrace Logo

Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases

NCT01048814 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 512

Last updated 2011-06-03

No results posted yet for this study

Summary

The purpose of this study is to improve upon and validate the prognostic and/or predictive accuracy of a drug response marker by the development of improved alternative algorithms based on the actual clinical outcome of retrospective cases.

Conditions

Interventions

OTHER

ChemoFx

Chemoresponse Marker Assay

Sponsors & Collaborators

  • Precision Therapeutics

    lead INDUSTRY

Principal Investigators

  • Holly Gallion, MD · Vice President, Clinical Affairs

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01048814 on ClinicalTrials.gov